Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael C. Bishop is active.

Publication


Featured researches published by Michael C. Bishop.


The Prostate | 2009

Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.

Thomas J. Walton; Geng Li; Thomas A. McCulloch; Rashmi Seth; Desmond G. Powe; Michael C. Bishop; Robert C. Rees

Real‐time quantitative RT‐PCR analysis of laser microdissected tissue is considered the most accurate technique for determining tissue gene expression. The discovery of estrogen receptor beta (ERβ) has focussed renewed interest on the role of estrogen receptors in prostate cancer, yet few studies have utilized the technique to analyze estrogen receptor gene expression in prostate cancer.


Urological Research | 2001

Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer.

Matthew S. Simms; Andrea Murray; Graeme Denton; David P. Scholfield; Michael R. Price; Alan C. Perkins; Michael C. Bishop

Abstract Current radiological techniques for staging bladder cancer are inaccurate, especially in the identification of pelvic lymph node metastases. Immunoscintigraphy has the potential to offer improved staging for bladder cancer. The aim of this study was to label the anti-MUC1 monoclonal antibody C595 with 99mtechnetium (Tc), the most widely used diagnostic radionuclide, and assess the potential of the resultant conjugate for intravenous immunoscintigraphy of bladder cancer. A direct, reduction-mediated technique was used to label the antibody. The resultant conjugate was shown to be highly immunoreactive, stable and bound specifically to MUC1. The ability of the conjugate to bind to bladder tumours was demonstrated in an ex vivo model where the mean tumour:normal urothelial uptake was 5.7:1 and by intravesical administration in patients with bladder cancer where the mean tumour:normal urothelial uptake was 20.4:1. The ability of the conjugate to localise MUC1-expressing tumours was demonstrated in a nude mouse xenograft model. A conjugate of 99mTc-C595 has been produced and characterised, and it may be suitable for intravenous immunoscintigraphy, a potential novel staging tool for bladder cancer.


The Prostate | 2008

DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.

T.J. Walton; Geng Li; R. Seth; Stephanie McArdle; Michael C. Bishop; Robert C. Rees


The Journal of Nuclear Medicine | 2001

Production and Characterization of 188Re-C595 Antibody for Radioimmunotherapy of Transitional Cell Bladder Cancer

Andrea Murray; Matthew S. Simms; David P. Scholfield; Rachel M. Vincent; Graeme Denton; Michael C. Bishop; Michael R. Price; Alan C. Perkins


European Urology | 2004

A Vaccination Strategy for the Long-Term Suppression of Androgens in Advanced Prostate Cancer

R.J. Parkinson; M.S. Simms; P. Broome; J.E. Humphreys; Michael C. Bishop


The Prostate | 2005

Obtaining fresh prostate cancer tissue for research: A novel biopsy needle and sampling technique for radical prostatectomy specimens

Thomas J. Walton; Thomas A. McCulloch; Robert C. Rees; Michael C. Bishop


The Prostate | 2003

Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy

Richard Parkinson; Shahid Mian; Michael C. Bishop; Trevor Gray; Geng Li; Stephanie McArdle; Selman Ali; Robert C. Rees


Journal of Urologic Pathology | 2000

MUC1 Mucin Expression in Transitional Cell Carcinoma of the Bladder: A Target Antigen for Diagnosis and Therapy with Monoclonal Antibody C595

O. D. Hughes; Helen Denley; Roger B. Kunkler; Graeme Denton; Michael R. Price; Alan C. Perkins; Michael C. Bishop


European Urology Supplements | 2008

FUNCTIONAL INVESTIGATION OF T21, A NOVEL CANCER-TESTIS ANTIGEN, USING RNA INTERFERENCE, REVEALS A ROLE IN PROSTATE CANCER CELL PROLIFERATION

A. Rogers; A. Miles; A. Grabowska; N. Graham; S. Watson; Michael C. Bishop; R. Rees


European Urology Supplements | 2007

86 DNA DEMETHYLATION AND HISTONE DEACETYLATION INHIBITION ACT SYNERGISTICALLY TO RE-EXPRESS OESTROGEN RECEPTOR BETA AND INDUCE APOPTOSIS IN PROSTATE CANCER CELL-LINES

T.J. Walton; R. Seth; Michael C. Bishop; R.C. Rees

Collaboration


Dive into the Michael C. Bishop's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

O. D. Hughes

University of Nottingham

View shared research outputs
Top Co-Authors

Avatar

Andrea Murray

University of Nottingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Graeme Denton

University of Nottingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert C. Rees

Nottingham Trent University

View shared research outputs
Top Co-Authors

Avatar

Geng Li

Nottingham Trent University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge